Krister Kauppi
Founder Rapamycin Longevity Lab
Founder, Rapamycin Longevity Lab
A community-driven lab accelerating research on mTOR inhibitors and developing longevity cocktails for living beyond 100 years.
Highlights
- Founded the Rapamycin Longevity Lab (Gothenburg, Sweden), a community-funded research effort screening mTOR-pathway modulators for longevity combination therapies.
- Lab experiments extended C. elegans lifespan by ~63% with the dual PI3K/mTOR inhibitor omipalisib, and up to 109% via an omipalisib plus doxycycline combination, exceeding rapamycin alone.
- Co-author of a 2025 GeroScience paper on the bioavailability and blood levels of low-dose rapamycin in real-world normative-aging cohorts, with AgelessRx.
- Built a scientific team including geroscience pioneer Brian Kennedy (former Buck Institute CEO) as advisor and researcher Kamil Pabis as scientific lead.
Founded the Rapamycin Longevity Lab (Gothenburg, Sweden), a community-funded research effort screening mTOR-pathway modulators for longevity combination therapies.. Lab experiments extended C. elegans lifespan by ~63% with the dual PI3K/mTOR inhibitor omipalisib, and up to 109% via an omipalisib plus doxycycline combination, exceeding rapamycin alone.. Co-author of a 2025 GeroScience paper on the bioavailability and blood levels of low-dose rapamycin in real-world normative-aging cohorts, with AgelessRx.. Built a scientific team including geroscience pioneer Brian Kennedy (former Buck Institute CEO) as advisor and researcher Kamil Pabis as scientific lead..
About Krister Kauppi
Krister Kauppi is the founder of the Rapamycin Longevity Lab, a community-driven research organisation in Gothenburg, Sweden, focused on mTOR inhibitors as the core of longevity combination therapies. Before longevity, he spent years as a senior software developer, including at DB Schenker, and studied at the University of Gothenburg.
The lab's mission is to extend rapamycin's legacy by using ultra-high-throughput lifespan assays – capable of running far faster than conventional models – together with AI-driven compound selection to find synergistic interventions beyond single-agent mTOR inhibition. Its work has explored compounds such as the dual PI3K/mTOR inhibitor omipalisib, reported to extend C. elegans lifespan substantially in early experiments.
Kauppi works with scientific advisors including Brian Kennedy and researcher Kamil Pabis, and is a co-author on a 2025 GeroScience paper on the bioavailability and blood levels of low-dose rapamycin in real-world cohorts, in collaboration with AgelessRx.
He is an active voice in the decentralised-science (DeSci) and longevity communities, advocating combination therapies rather than single interventions to address ageing.
Credentials
- OtherBSc Informatics (Decision Support Systems)— University of Gothenburg(2001)
Education
Topics & Expertise
- Aging Biology & Senolytics
- Pharmaceuticals & Supplements
- Metabolic Health
- rapamycin and mTOR inhibition
- longevity combination therapies
- PI3K/mTOR dual inhibition
- high-throughput C. elegans lifespan assays
- AI-driven compound selection
- decentralised science (DeSci)
Talks at Longevity Cities
Past
- Don't Die Longevity & Rapamycin — Oct 25, 2024 · Blutenburgstraße 59, München
Frequently Asked
Who is Krister Kauppi?
Krister Kauppi is the founder of the Rapamycin Longevity Lab, a community-driven research organisation in Gothenburg, Sweden, focused on mTOR inhibitors and combination therapies for longevity. Before longevity, he worked for years as a senior software developer, including at DB Schenker (Schenker Dedicated Services).
What does the Rapamycin Longevity Lab do?
The Rapamycin Longevity Lab, founded by Krister Kauppi, uses high-throughput C. elegans lifespan assays and AI-driven compound selection to find interventions beyond single-agent rapamycin. It develops mTOR-inhibitor-based combination therapies aimed at pushing the boundaries of human longevity.
What compounds has the Rapamycin Longevity Lab studied?
The lab screens mTOR-pathway modulators for synergy. Its experiments reported that the dual PI3K/mTOR inhibitor omipalisib extended C. elegans lifespan by about 63%, while an omipalisib plus doxycycline combination reached up to 109%, both exceeding the gains of rapamycin alone. It also explores conservative combinations of FDA-approved drugs such as rapamycin plus doxycycline.
Who are the scientific advisors of the Rapamycin Longevity Lab?
The Rapamycin Longevity Lab works with geroscience pioneer Brian Kennedy, former CEO of the Buck Institute, as scientific advisor, and translational aging researcher and bioinformatics specialist Kamil Pabis as scientific lead. Krister Kauppi founded the community-driven lab in Gothenburg, Sweden.
What is Krister Kauppi's background?
Krister Kauppi holds a Bachelor's degree in Informatics (Decision Support Systems) from the University of Gothenburg and spent years as a senior software developer, including at DB Schenker, before focusing full time on longevity research and founding the Rapamycin Longevity Lab.